<li>acarbose<p>hydrochlorothiazide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>aceclofenac<p>triamterene, aceclofenac. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>aceclofenac increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of aceclofenac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>acemetacin<p>triamterene, acemetacin. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of acemetacin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>acemetacin increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>acyclovir<p>hydrochlorothiazide will increase the level or effect of acyclovir by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>agrimony<p>agrimony increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>agrimony<p>agrimony increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>albuterol<p>albuterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>aminohippurate sodium<p>hydrochlorothiazide will increase the level or effect of aminohippurate sodium by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>ampicillin<p>hydrochlorothiazide increases levels of ampicillin by decreasing renal clearance. Minor/Significance Unknown.</p></li><li>arformoterol<p>arformoterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>aspirin<p>triamterene, aspirin. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>aspirin increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>aspirin rectal<p>aspirin rectal increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>triamterene, aspirin rectal. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of aspirin rectal by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>hydrochlorothiazide will increase the level or effect of aspirin/citric acid/sodium bicarbonate by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>aspirin/citric acid/sodium bicarbonate increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>triamterene, aspirin/citric acid/sodium bicarbonate. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.</p></li><li>balsalazide<p>hydrochlorothiazide will increase the level or effect of balsalazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>birch<p>birch increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>bambuterol<p>bambuterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>bendroflumethiazide<p>bendroflumethiazide will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>birch<p>birch increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>bitter melon<p>bitter melon, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>brimonidine<p>brimonidine increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.<span><br><br></span>brimonidine increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>budesonide<p>budesonide, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>cadexomer iodine<p>cadexomer iodine, triamterene. Mechanism: decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.</p></li><li>calcitriol topical<p>calcitriol topical, hydrochlorothiazide.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Potential additive hypercalcemia.</p></li><li>calcium acetate<p>triamterene decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.</p></li><li>calcium carbonate<p>hydrochlorothiazide increases levels of calcium carbonate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.<span><br><br></span>triamterene decreases levels of calcium carbonate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>calcium chloride<p>hydrochlorothiazide increases levels of calcium chloride by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.<span><br><br></span>triamterene decreases levels of calcium chloride by increasing renal clearance. Minor/Significance Unknown.</p></li><li>calcium citrate<p>hydrochlorothiazide increases levels of calcium citrate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.<span><br><br></span>triamterene decreases levels of calcium citrate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>calcium gluconate<p>hydrochlorothiazide increases levels of calcium gluconate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.<span><br><br></span>triamterene decreases levels of calcium gluconate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>carbenoxolone<p>hydrochlorothiazide, carbenoxolone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypokalemic effects.</p></li><li>celecoxib<p>triamterene, celecoxib. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>celecoxib increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>cefadroxil<p>cefadroxil will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>cefamandole<p>cefamandole will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>cefpirome<p>cefpirome will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>cefprozil<p>cefprozil will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>ceftibuten<p>ceftibuten will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>ceftizoxime<p>ceftizoxime will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>celecoxib<p>hydrochlorothiazide will increase the level or effect of celecoxib by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>cephalexin<p>cephalexin will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>chlorothiazide<p>chlorothiazide will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>chlorpropamide<p>hydrochlorothiazide will increase the level or effect of chlorpropamide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide decreases effects of chlorpropamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>chlorthalidone<p>chlorthalidone will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>choline magnesium trisalicylate<p>triamterene, choline magnesium trisalicylate. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>choline magnesium trisalicylate increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>clobetasone<p>clobetasone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>colestipol<p>colestipol decreases levels of hydrochlorothiazide by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>cornsilk<p>cornsilk increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>cortisone<p>cortisone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>cosyntropin<p>cosyntropin, hydrochlorothiazide. pharmacodynamic synergism. Minor/Significance Unknown. Possible enhanced electrolyte loss.</p></li><li>cyclopenthiazide<p>cyclopenthiazide will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>deflazacort<p>deflazacort, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>dexamethasone<p>dexamethasone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>diazoxide<p>diazoxide, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hyperglycemia.</p></li><li>diclofenac<p>hydrochlorothiazide will increase the level or effect of diclofenac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>diclofenac increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>triamterene, diclofenac. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.</p></li><li>diflunisal<p>diflunisal increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of diflunisal by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>triamterene, diflunisal. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of hydrochlorothiazide by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>diltiazem will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>dobutamine<p>dobutamine, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>epoprostenol<p>epoprostenol increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.</p></li><li>dopexamine<p>dopexamine, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>ephedrine<p>ephedrine, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>ephedrine (pulmonary)<p>ephedrine (pulmonary), hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>epinephrine<p>epinephrine, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>epinephrine racemic<p>epinephrine racemic, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>epoprostenol<p>epoprostenol increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.</p></li><li>etodolac<p>etodolac increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of etodolac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>triamterene, etodolac. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.</p></li><li>etoricoxib<p>etoricoxib increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>triamterene, etoricoxib. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of etoricoxib by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>fenbufen<p>fenbufen increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>triamterene, fenbufen. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of fenbufen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>fenoprofen<p>triamterene, fenoprofen. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>fenoprofen increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of fenoprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>fludrocortisone<p>fludrocortisone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>flurbiprofen<p>triamterene, flurbiprofen. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>flurbiprofen increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>flurbiprofen<p>hydrochlorothiazide will increase the level or effect of flurbiprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>fo-ti<p>fo-ti increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).</p></li><li>folic acid<p>triamterene decreases levels of folic acid by increasing renal clearance. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide decreases levels of folic acid by increasing renal clearance. Minor/Significance Unknown.</p></li><li>formoterol<p>formoterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>forskolin<p>forskolin increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>forskolin<p>forskolin increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>ganciclovir<p>hydrochlorothiazide will increase the level or effect of ganciclovir by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>glimepiride<p>hydrochlorothiazide decreases effects of glimepiride by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>glipizide<p>hydrochlorothiazide decreases effects of glipizide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>gliquidone<p>hydrochlorothiazide decreases effects of gliquidone by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>glyburide<p>hydrochlorothiazide decreases effects of glyburide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>goldenrod<p>goldenrod increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.<span><br><br></span>goldenrod increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>hydrochlorothiazide<p>hydrochlorothiazide will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>hydrocortisone<p>hydrocortisone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>ibuprofen<p>triamterene, ibuprofen. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of ibuprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>ibuprofen increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>indapamide<p>hydrochlorothiazide will increase the level or effect of indapamide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>indomethacin<p>triamterene, indomethacin. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>indomethacin increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>indomethacin<p>hydrochlorothiazide will increase the level or effect of indomethacin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>insulin aspart<p>hydrochlorothiazide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>insulin detemir<p>hydrochlorothiazide decreases effects of insulin detemir by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>insulin glargine<p>hydrochlorothiazide decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>insulin glulisine<p>hydrochlorothiazide decreases effects of insulin glulisine by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>insulin lispro<p>hydrochlorothiazide decreases effects of insulin lispro by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>insulin nph<p>hydrochlorothiazide decreases effects of insulin nph by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>insulin regular human<p>hydrochlorothiazide decreases effects of insulin regular human by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>iodinated glycerol<p>iodinated glycerol, triamterene. Mechanism: decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.</p></li><li>iodine<p>iodine, triamterene. Mechanism: decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.</p></li><li>isoproterenol<p>isoproterenol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>ketoprofen<p>triamterene, ketoprofen. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>ketoprofen increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of ketoprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>ketorolac<p>triamterene, ketorolac. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of ketorolac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>ketorolac increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>ketorolac intranasal<p>ketorolac intranasal increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>triamterene, ketorolac intranasal. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of ketorolac intranasal by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>l-methylfolate<p>hydrochlorothiazide decreases levels of l-methylfolate by increasing renal clearance. Minor/Significance Unknown.<span><br><br></span>triamterene decreases levels of l-methylfolate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>levalbuterol<p>levalbuterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>lofexidine<p>lofexidine increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>lofexidine<p>lofexidine increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>lornoxicam<p>triamterene, lornoxicam. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>lornoxicam increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of lornoxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>magnesium chloride<p>triamterene increases levels of magnesium chloride by decreasing renal clearance. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide decreases levels of magnesium chloride by increasing renal clearance. Minor/Significance Unknown.</p></li><li>magnesium citrate<p>triamterene increases levels of magnesium citrate by decreasing renal clearance. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide decreases levels of magnesium citrate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>magnesium hydroxide<p>hydrochlorothiazide decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.<span><br><br></span>triamterene increases levels of magnesium hydroxide by decreasing renal clearance. Minor/Significance Unknown.</p></li><li>magnesium oxide<p>hydrochlorothiazide decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.<span><br><br></span>triamterene increases levels of magnesium oxide by decreasing renal clearance. Minor/Significance Unknown.</p></li><li>magnesium sulfate<p>hydrochlorothiazide decreases levels of magnesium sulfate by increasing renal clearance. Minor/Significance Unknown.<span><br><br></span>triamterene increases levels of magnesium sulfate by decreasing renal clearance. Minor/Significance Unknown.</p></li><li>maitake<p>maitake increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>meclofenamate<p>hydrochlorothiazide will increase the level or effect of meclofenamate by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>meclofenamate<p>meclofenamate increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>triamterene, meclofenamate. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.</p></li><li>mefenamic acid<p>mefenamic acid increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of mefenamic acid by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>triamterene, mefenamic acid. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.</p></li><li>meloxicam<p>meloxicam increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>triamterene, meloxicam. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.</p></li><li>memantine<p>hydrochlorothiazide will increase the level or effect of memantine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>memantine will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>mesalamine<p>hydrochlorothiazide will increase the level or effect of mesalamine by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>metformin<p>metformin will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>metaproterenol<p>metaproterenol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>metformin<p>hydrochlorothiazide will increase the level or effect of metformin by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide decreases effects of metformin by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>methotrexate<p>hydrochlorothiazide increases toxicity of methotrexate by decreasing elimination. Minor/Significance Unknown. Increased myelosuppression.</p></li><li>methyclothiazide<p>methyclothiazide will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>methylprednisolone<p>methylprednisolone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>metolazone<p>hydrochlorothiazide will increase the level or effect of metolazone by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>midodrine<p>midodrine will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide will increase the level or effect of midodrine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>miglitol<p>hydrochlorothiazide decreases effects of miglitol by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>minoxidil<p>triamterene increases effects of minoxidil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>minoxidil<p>hydrochlorothiazide increases effects of minoxidil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>nabumetone<p>nabumetone increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>triamterene, nabumetone. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of nabumetone by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>naproxen<p>naproxen increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of naproxen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>triamterene, naproxen. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.</p></li><li>nateglinide<p>hydrochlorothiazide decreases effects of nateglinide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>octacosanol<p>octacosanol increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>noni juice<p>noni juice increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>norepinephrine<p>norepinephrine, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.<span><br><br></span>hydrochlorothiazide decreases effects of norepinephrine by pharmacodynamic antagonism. Minor/Significance Unknown. May decrease responsiveness to norepinephrine but not enough to preclude effectiveness of the pressor agent therapeutic use.</p></li><li>octacosanol<p>octacosanol increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>ofloxacin<p>hydrochlorothiazide will increase the level or effect of ofloxacin by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>ofloxacin will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>oxaprozin<p>oxaprozin increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>triamterene, oxaprozin. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of oxaprozin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>parecoxib<p>hydrochlorothiazide will increase the level or effect of parecoxib by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>parecoxib increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>triamterene, parecoxib. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.</p></li><li>penicillin g aqueous<p>hydrochlorothiazide increases levels of penicillin g aqueous by decreasing renal clearance. Minor/Significance Unknown.</p></li><li>piroxicam<p>triamterene, piroxicam. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>piroxicam increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>penicillin vk<p>hydrochlorothiazide increases levels of penicillin vk by decreasing renal clearance. Minor/Significance Unknown.</p></li><li>pioglitazone<p>hydrochlorothiazide decreases effects of pioglitazone by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>piperacillin<p>hydrochlorothiazide increases levels of piperacillin by decreasing renal clearance. Minor/Significance Unknown.</p></li><li>pirbuterol<p>pirbuterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>piroxicam<p>hydrochlorothiazide will increase the level or effect of piroxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>potassium iodide<p>potassium iodide, triamterene. Mechanism: decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.</p></li><li>pramipexole<p>pramipexole will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>prednisolone<p>prednisolone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>prednisone<p>prednisone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>quinine<p>quinine will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide will increase the level or effect of quinine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>ranitidine<p>ranitidine will decrease the level or effect of triamterene by  unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide will increase the level or effect of ranitidine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>reishi<p>reishi increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.<span><br><br></span>reishi increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>repaglinide<p>hydrochlorothiazide decreases effects of repaglinide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>salicylates (non-asa)<p>triamterene, salicylates (non-asa). Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>salicylates (non-asa) increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>rose hips<p>rose hips will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>rosiglitazone<p>hydrochlorothiazide decreases effects of rosiglitazone by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>salicylates (non-asa)<p>hydrochlorothiazide will increase the level or effect of salicylates (non-asa) by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>salmeterol<p>salmeterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>salsalate<p>triamterene, salsalate. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>salsalate increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of salsalate by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>saxagliptin<p>hydrochlorothiazide decreases effects of saxagliptin by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>shepherd's purse<p>shepherd's purse, triamterene. Other (see comment). Minor/Significance Unknown. 
Comment: Theoretically, shepherd's purse may interfere with BP control.</p></li><li>shepherd's purse<p>shepherd's purse, hydrochlorothiazide. Other (see comment). Minor/Significance Unknown. 
Comment: Theoretically, shepherd's purse may interfere with BP control.</p></li><li>sitagliptin<p>hydrochlorothiazide decreases effects of sitagliptin by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>sulfadiazine<p>triamterene increases levels of sulfadiazine by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide increases levels of sulfadiazine by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>sulfamethoxazole<p>sulfamethoxazole will increase the level or effect of hydrochlorothiazide by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>triamterene, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.<span><br><br></span>triamterene increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.<span><br><br></span>sulfamethoxazole will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>sulfasalazine<p>triamterene, sulfasalazine. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>sulfasalazine increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of sulfasalazine by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>sulfisoxazole<p>triamterene increases levels of sulfisoxazole by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide increases levels of sulfisoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>sulindac<p>triamterene, sulindac. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of sulindac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>sulindac increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.</p></li><li>terbutaline<p>terbutaline, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.<span><br><br></span>hydrochlorothiazide, terbutaline. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypokalemic effects.</p></li><li>tizanidine<p>tizanidine increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.</p></li><li>tizanidine<p>tizanidine increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.</p></li><li>tolazamide<p>hydrochlorothiazide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>tolbutamide<p>hydrochlorothiazide decreases effects of tolbutamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>tolfenamic acid<p>tolfenamic acid increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>hydrochlorothiazide will increase the level or effect of tolfenamic acid by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>triamterene, tolfenamic acid. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.</p></li><li>tolmetin<p>hydrochlorothiazide will increase the level or effect of tolmetin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>tolmetin increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.<span><br><br></span>triamterene, tolmetin. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of acute renal failure.  Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.</p></li><li>treprostinil<p>treprostinil increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.<span><br><br></span>treprostinil increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>triamcinolone<p>triamcinolone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>trimethoprim<p>triamterene will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>triamterene, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.</p></li><li>triamterene<p>hydrochlorothiazide will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>trilostane<p>trilostane, hydrochlorothiazide. Other (see comment). Minor/Significance Unknown. 
Comment: Trilostane reduces K+ loss while maintaining the natriuretic effect.  Mechanism:  inhibition of mineralocorticoid steroid synthesis.</p></li><li>trimethoprim<p>hydrochlorothiazide will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.</p></li><li>troglitazone<p>hydrochlorothiazide decreases effects of troglitazone by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>valganciclovir<p>hydrochlorothiazide will increase the level or effect of valganciclovir by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>verapamil<p>hydrochlorothiazide will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>triamterene will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>verteporfin<p>hydrochlorothiazide, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity.</p></li><li>vildagliptin<p>hydrochlorothiazide decreases effects of vildagliptin by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage &gt;50 mg/day may increase blood glucose.</p></li><li>willow bark<p>hydrochlorothiazide will increase the level or effect of willow bark by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li>